BioMark Diagnostics, Inc.

As of June 30, 2026, BioMark Diagnostics, Inc. carries a market capitalization of 58.57M, placing it among publicly traded companies globally. Its enterprise value stands at 59.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, BioMark Diagnostics, Inc. has 106.48M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2,085.17, and the price-to-book ratio stands at 102.53.

These figures are as of June 30, 2026. The EV/Sales ratio of 2,123.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 59.05M versus a market cap of 58.57M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioMark Diagnostics, Inc. maintains a current ratio of 1.29, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 222.55, indicating elevated leverage, while an interest coverage ratio of -13.49 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioMark Diagnostics, Inc. posted a negative return on equity (ROE) of -149.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -59.10, reflecting losses generated across the asset base. The company generates approximately 6,950.75 in revenue per employee across its workforce of 4.00, a quick read on workforce productivity versus industry peers.

As of the close on October 20, 2026, BioMark Diagnostics, Inc.'s stock has gained approximately 32.39% over the past 52 weeks. The 50-day moving average sits at 0.53, while the 200-day moving average is 0.50.

Over the twelve months ended June 30, 2026, BioMark Diagnostics, Inc. generated 27,803.00 in revenue and converted that into -1.43M in net income, yielding earnings per share of -0.01. EBITDA reached -1.04M, while operating income came in at -1.43M.

As of June 30, 2026, BioMark Diagnostics, Inc. holds 788,323.00 in cash and equivalents against 1.27M in total debt, resulting in a net debt position of -729,798.00. Total book value stands at 571,207.00, with working capital of 193,421.00 providing operational flexibility.

BioMark Diagnostics, Inc. produced -1.06M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2,229.00 in capital expenditures, free cash flow totaled -1.07M - equivalent to -0.01 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -5,154.95 and net profit margin of -5,127.11 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.84: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.41, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioMark Diagnostics, Inc. shareholders.

As of June 30, 2026, BioMark Diagnostics, Inc. has an Altman Z-Score of 8.58, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.